Michelle Morrow

3.8k total citations · 1 hit paper
34 papers, 2.0k citations indexed

About

Michelle Morrow is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Michelle Morrow has authored 34 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Immunology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Michelle Morrow's work include Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (14 papers) and Acute Myeloid Leukemia Research (6 papers). Michelle Morrow is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), Immunotherapy and Immune Responses (14 papers) and Acute Myeloid Leukemia Research (6 papers). Michelle Morrow collaborates with scholars based in United Kingdom, United States and Canada. Michelle Morrow's co-authors include Ross Stewart, Robert W. Wilkinson, Simon J. Dovedi, Jamie Honeychurch, Edmund Poon, Tim Illidge, Eleanor J. Cheadle, Grazyna Lipowska‐Bhalla, Amy L. Adlard and Ian J. Stratford and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Michelle Morrow

32 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

2014 974 citations Simon J. Dovedi, Amy L. Adlard et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle Morrow United Kingdom	14	1.3k	725	466	434	212	34	2.0k
Martin Erlanson Sweden	25	1.2k 0.9×	543 0.7×	364 0.8×	415 1.0×	128 0.6×	67	2.3k
Carol O’Hear United States	25	2.1k 1.5×	718 1.0×	680 1.5×	378 0.9×	165 0.8×	58	2.4k
Elena Hartmann Germany	26	992 0.7×	619 0.9×	259 0.6×	675 1.6×	167 0.8×	80	2.6k
Emma C. Scott United States	10	2.3k 1.7×	1.3k 1.8×	346 0.7×	661 1.5×	111 0.5×	27	3.2k
Robert Chen United States	31	3.4k 2.5×	963 1.3×	484 1.0×	411 0.9×	555 2.6×	81	4.7k
Alex F. Herrera United States	28	2.5k 1.9×	642 0.9×	218 0.5×	392 0.9×	366 1.7×	239	3.5k
Lapo Alinari United States	30	793 0.6×	518 0.7×	419 0.9×	623 1.4×	487 2.3×	115	2.8k
Deepika Cattry United States	3	2.2k 1.6×	1.2k 1.7×	333 0.7×	285 0.7×	99 0.5×	4	2.7k
Wojciech Jurczak Poland	22	1.5k 1.1×	717 1.0×	289 0.6×	496 1.1×	345 1.6×	281	3.4k
Radhakrishnan Ramchandren United States	26	3.1k 2.3×	977 1.3×	457 1.0×	408 0.9×	551 2.6×	88	4.6k

Countries citing papers authored by Michelle Morrow

Since Specialization

Citations

This map shows the geographic impact of Michelle Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Morrow more than expected).

Fields of papers citing papers by Michelle Morrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Morrow. The network helps show where Michelle Morrow may publish in the future.

Co-authorship network of co-authors of Michelle Morrow

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Morrow. A scholar is included among the top collaborators of Michelle Morrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Morrow. Michelle Morrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Imianowski, Charlotte J., Paula Kuo, Sarah K. Whiteside, et al.. (2024). IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy. Cancer Research Communications. 4(8). 2045–2057. 3 indexed citations

Morrow, Michelle, Erin Torti, Kirsty McWalter, et al.. (2024). MGA-related syndrome: A proposed novel disorder. Human Genetics and Genomics Advances. 6(1). 100387–100387.

Walker, Jennifer A., Michelle Morrow, Viia Valge-Archer, et al.. (2023). Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments. Frontiers in Immunology. 14. 1258291–1258291. 9 indexed citations

Chan, Christopher T., et al.. (2023). Weekly Proactive Telephone Breastfeeding Standard Care by Lactation Consultants in the First Month Postpartum Prolongs Breastfeeding for Up to 6 Months. Nutrients. 15(9). 2075–2075. 5 indexed citations

Holz, Josefin-Beate, et al.. (2022). Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report. Journal for ImmunoTherapy of Cancer. 10(10). e005225–e005225. 6 indexed citations

Kraman, Matthew, Mustapha Faroudi, Daniel Gliddon, et al.. (2020). FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity. Clinical Cancer Research. 26(13). 3333–3344. 82 indexed citations

Gaspar, Miguel, et al.. (2020). CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement. Cancer Immunology Research. 8(6). 781–793. 43 indexed citations

Dovedi, Simon J., Eleanor J. Cheadle, Edmund Poon, et al.. (2017). Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clinical Cancer Research. 23(18). 5514–5526. 263 indexed citations

Dovedi, Simon J., Amy L. Adlard, Grazyna Lipowska‐Bhalla, et al.. (2014). Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research. 74(19). 5458–5468. 974 indexed citations breakdown →

10.

Dovedi, Simon J., Amy L. Adlard, Grazyna Lipowska‐Bhalla, et al.. (2014). The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Journal for ImmunoTherapy of Cancer. 2(S3). 3 indexed citations

11.

Hooijkaas, Anna I., Jules Gadiot, Michelle Morrow, et al.. (2012). Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology. 1(5). 609–617. 60 indexed citations

12.

Stewart, Ross, Michelle Morrow, Matthieu Chodorge, et al.. (2011). Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development. Cancer Research. 71(8_Supplement). LB–158. 7 indexed citations

13.

Roudaia, Liya, Matthew D. Cheney, Wei Chen, et al.. (2009). CBFβ is critical for AML1-ETO and TEL-AML1 activity. Blood. 113(13). 3070–3079. 40 indexed citations

14.

Salek‐Ardakani, Samira, Jasper de Boer, Neil J. Sebire, et al.. (2009). ERG Is a Megakaryocytic Oncogene. Cancer Research. 69(11). 4665–4673. 84 indexed citations

15.

Gefen, N. E., Vera Binder, Markéta Žaliová, et al.. (2009). Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia. 24(1). 89–96. 92 indexed citations

16.

Lyons, Ruth J., Owen Williams, Michelle Morrow, et al.. (2009). The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. Leukemia Research. 34(1). 109–115. 4 indexed citations

17.

Truong, Vouy Linh & Michelle Morrow. (2009). Mild and efficient ligand-free copper-catalyzed condensation for the synthesis of quinazolines. Tetrahedron Letters. 51(4). 758–760. 70 indexed citations

18.

Morrow, Michelle, A. Samanta, D Kioussis, Hugh J.M. Brady, & Owen Williams. (2007). TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene. 26(30). 4404–4414. 31 indexed citations

19.

Horton, Sarah J., David G. Grier, Alexander Thompson, et al.. (2005). Continuous MLL-ENL Expression Is Necessary to Establish a “Hox Code” and Maintain Immortalization of Hematopoietic Progenitor Cells. Cancer Research. 65(20). 9245–9252. 55 indexed citations

20.

Morrow, Michelle, Sarah J. Horton, Dimitris Kioussis, Hugh J.M. Brady, & Owen Williams. (2004). TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood. 103(10). 3890–3896. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact